Literature DB >> 31336198

Rate of Reoperation Decreased Significantly After Year 2002 in Patients With Crohn's Disease.

Takahide Shinagawa1, Keisuke Hata2, Hiroki Ikeuchi3, Kouhei Fukushima4, Kitaro Futami5, Akira Sugita6, Motoi Uchino3, Kazuhiro Watanabe7, Daijiro Higashi5, Hideaki Kimura8, Toshimitsu Araki9, Tsunekazu Mizushima10, Michio Itabashi11, Takeshi Ueda12, Kazutaka Koganei6, Koji Oba13, Soichiro Ishihara1, Yasuo Suzuki14.   

Abstract

BACKGROUND & AIMS: Patients with Crohn's disease (CD) can require multiple intestinal surgeries. We examined time trends and risk factors for reoperation in patients with CD who underwent intestinal surgery, focusing on the effects of postoperative medical treatments.
METHODS: We performed a retrospective analysis of 1871 patients with CD who underwent initial intestinal resection at 10 tertiary care institutions in Japan, with an initial surgical date after May 1982. We collected data on the background characteristics of all patients, including Montreal Classification, smoking status, and medical therapy after surgery (tumor necrosis factor antagonists [anti-TNF] agents or immunomodulators). The primary outcome was requirement for first reoperation. Rate of reoperation was estimated using the Kaplan-Meier method, and risk factors for reoperation were identified using the Cox regression model.
RESULTS: The overall cumulative 5- and 10-year reoperation rates were 23.4% and 48.0%, respectively. Multivariable analysis showed that patients who underwent the initial surgery after May 2002 had a significantly lower rate of reoperation than patients who underwent surgery before April 2002 (hazard ratio [HR], 0.72; 95% CI, 0.61-0.86). Preoperative smoking (HR, 1.40; 95% CI, 1.18-1.68), perianal disease (HR, 1.50; 95% CI, 1.27-1.77), and ileocolic type of CD (HR, 1.42; 95% CI, 1.20-1.69) were significant risk factors for reoperation. Postoperative use of immunomodulators (HR, 0.60; 95% CI, 0.44-0.81) and anti-TNF therapy (HR, 0.71; 95% CI, 0.57-0.88) significantly reduced the risk. Anti-TNF was effective in the bionaive subgroup.
CONCLUSIONS: The rate of reoperation in patients with CD significantly decreased after May 2002. Postoperative use of anti-TNF agents might reduce the reoperation rate for bionaive patients with CD.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Environmental Factor; IBD; Inflammatory Bowel Disease; Outcomes

Year:  2019        PMID: 31336198     DOI: 10.1016/j.cgh.2019.07.025

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  8 in total

Review 1.  Surgical Techniques and Risk of Postoperative Recurrence in CD: A Game Changer?

Authors:  Gaetano Luglio; Toru Kono
Journal:  Inflamm Intest Dis       Date:  2021-05-21

Review 2.  What's New in the Postoperative Management of Crohn's Disease?

Authors:  Sonya S Dasharathy; Berkeley N Limketkai; Jenny S Sauk
Journal:  Dig Dis Sci       Date:  2021-08-18       Impact factor: 3.487

3.  The safety and feasibility of laparoscopic redo surgery for recurrent Crohn's disease: A comparative clinical study of over 100 consecutive patients.

Authors:  Takayuki Ogino; Yuki Sekido; Tsuyoshi Hata; Norikatsu Miyoshi; Hidekazu Takahashi; Mamoru Uemura; Hirofumi Yamamoto; Yuichiro Doki; Hidetoshi Eguchi; Tsunekazu Mizushima
Journal:  Ann Gastroenterol Surg       Date:  2021-12-16

4.  Essential updates 2018/2019: Colorectal (benign): Recent updates (2018-2019) in the surgical treatment of benign colorectal diseases.

Authors:  Takayuki Ogino; Tsunekazu Mizushima; Chu Matsuda; Masaki Mori; Yuichiro Doki
Journal:  Ann Gastroenterol Surg       Date:  2019-12-16

Review 5.  Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts.

Authors:  Lester Tsai; Christopher Ma; Parambir S Dulai; Larry J Prokop; Samuel Eisenstein; Sonia L Ramamoorthy; Brian G Feagan; Vipul Jairath; William J Sandborn; Siddharth Singh
Journal:  Clin Gastroenterol Hepatol       Date:  2020-10-27       Impact factor: 13.576

6.  Optimal use of biologics with endoscopic balloon dilatation for repeated intestinal strictures in Crohn's disease.

Authors:  Akihito Uda; Hiroyo Kuwabara; Sayuri Shimizu; Ryuichi Iwakiri; Kiyohide Fushimi
Journal:  JGH Open       Date:  2020-03-28

7.  Inflammatory Bowel Disease Reoperation Rate Has Decreased Over Time If Corrected by Prevalence.

Authors:  Mafalda Santiago; Fernando Magro; Luís Correia; Francisco Portela; Paula Ministro; Paula Lago; Eunice Trindade; Cláudia Camila Dias
Journal:  Clin Transl Gastroenterol       Date:  2020-09       Impact factor: 4.396

8.  Antimesenteric cutback end-to-end isoperistaltic anastomosis (Sasaki-Watanabe anastomosis) for Crohn's disease: Novel surgical technique and early results of surgical anastomotic recurrence.

Authors:  Kazuhiro Watanabe; Iwao Sasaki; Atsushi Kohyama; Hideyuki Suzuki; Minoru Kobayashi; Taiki Kajiwara; Hideaki Karasawa; Shinobu Ohnuma; Takashi Kamei; Michiaki Unno
Journal:  Ann Gastroenterol Surg       Date:  2021-02-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.